The following table summarizes the carrying amounts of goodwill at June 30, 2026 and December 31, 2025 (in thousands):


	Goodwill Carrying Amount
Balance as of December 31, 2024	$	522,766
Acquired goodwill(1)	5,078
Impairment charges(2)	(3,500)
Balance as of December 31, 2025	$	524,344
Acquired goodwill adjustment(1)	(349)

Balance as of June 30, 2026	$	523,995

(1) In connection with the acquisition of Pathline, the Company recognized $5.1 million of goodwill during the year ended December 31, 2025 and an adjustment of $0.3 million during the six months ended June 30, 2026, reflecting the allocation of the purchase price to the identifiable assets acquired and liabilities assumed. Please refer to Note 3. Acquisitions and Disposals for further information about the acquisition of Pathline.

(2) In connection with the classification of the Trapelo assets as held for sale, the Company recognized an impairment charge of $3.5 million to write down the carrying value of the disposal group to its estimated fair value less costs to sell. Please refer to Note 3. Acquisitions and Disposals for further information about the sale of Trapelo.

Intangible assets consisted of the following (in thousands):


		June 30, 2026
	Amortization Period (years)	Cost		Accumulated Amortization		Net


Customer Relationships	7 - 15	$	144,301	$	90,471	$	53,830
Developed Technology	10 - 15	276,825		92,942		183,883

Trademarks	15	30,261		10,159		20,102

Trademark - Indefinite lived	—	13,447		—		13,447
Total		$	464,834	$	193,572	$	271,262


		December 31, 2025
	Amortization Period (years)	Cost		Accumulated Amortization		Net
Customer Relationships(1)	7 - 15	$	144,301	$	85,441	$	58,860
Developed Technology(2)	10 - 15	276,825		83,714		193,111

Trademarks(3)	15	30,261		9,151		21,110
Trade Name	2.5	2,584		2,584		—
Trademark - Indefinite lived	—	13,447		—		13,447
Total		$	467,418	$	180,890	$	286,528

(1) Includes $1.2 million of acquired client relationships related to Pathline. Please refer to Note 3. Acquisitions and Disposals for further information about the acquisition of Pathline.

(2) Includes an impairment loss of $10.5 million on InVisionFirst®-Lung developed technology and an adjustment of $12.4 million related to the classification of Trapelo as held for sale. Please refer to Note 3. Acquisitions and Disposals for further information about the disposal of Trapelo assets.

The Company records amortization expense within cost of revenue and general and administrative expense on the Consolidated Statement of Operations. The following table summarizes the amortization expense for the three and six months ended June 30, 2026 and 2025 (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2026		2025		2026		2025
Amortization of intangibles included in cost of revenue	$	4,614	$	4,811	$	9,228	$	9,721
Amortization of intangibles included in general and administrative expenses	3,020		3,313		6,039		6,765
Total amortization of intangibles	$	7,634	$	8,124	$	15,267	$	16,486

The estimated amortization expense related to amortizable intangible assets for each of the following periods as of June 30, 2026 is as follows (in thousands):


Remainder of 2026	$	15,267
2027	29,983
2028	29,983
2029	29,983
2030	29,530

Thereafter	123,069
Total	$	257,815

During the three and six months ended June 30, 2025, the Company recorded impairment charges of $11.4 million and an inventory write-off of $0.4 million associated with InVisionFirst®-Lung, a legacy diagnostic test. Impairment charges consisted of a $10.5 million loss on developed technology and a $0.9 million loss on trademarks. The impairment charge and inventory write-off were included within impairment charges on the Consolidated Statements of Operations. There were no such costs for the three and six months ended June 30, 2026.